Immunotherapy resistance: The answers lie ahead - not in front - of us

11Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

Mechanisms of innate and adaptive resistance to checkpoint blockade immunotherapy are under intense investigation with a view to broadening the therapeutic potential of this form of treatment. In a recent manuscript by Zaretsky and colleagues, mutational events were identified that effectively crippled ongoing immunotherapy responses in patients treated with anti-PD-1 therapy. These results are discussed in the light of other recent and ongoing research efforts exploring both mutational and non-mutational resistance mechanisms, highlighting the critical translational importance of longitudinal tumor sampling.

Cite

CITATION STYLE

APA

Andrews, M. C., & Wargo, J. A. (2017, February 21). Immunotherapy resistance: The answers lie ahead - not in front - of us. Journal for ImmunoTherapy of Cancer. BioMed Central Ltd. https://doi.org/10.1186/s40425-017-0212-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free